Navigation Links
Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics
Date:10/21/2010

tibodies using existing non-proprietary chelates , Algeta has already demonstrated in vivo the potential of its proprietary technology for enhancing the performance of radio-immunotherapies based on existing clinical antibodies. We believe that the new chelators will provide even better results."

Lumi4® complexes are a new class of metal lanthanide and actinide chelators based on technology patented by Professor Kenneth N. Raymond and coworkers at the University of California, Berkeley and modified by Lumiphore. This unique patent family is focused on a novel cage structure surrounding lanthanide ions which enables them to be tightly held and covalently attached to receptor targeting molecules.

This is the fourth major agreement reached by Lumiphore in the past four years. Previous partnerships include Thermo Fisher Scientific Specialty Diagnostics (www.thermofisher.com) for certain diagnostic tests to be used in both in laboratories and point-of-care-formats including Downs Syndrome; Cis Bio International (www.htrf.com/company/partners/) for the drug discovery research market; and Biophor Diagnostics Inc. (www.biophor.com) for diagnostic tests for drugs of abuse.

About Lumiphore, Inc.Based in Richmond, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary fluorescent-metal lanthanide and chelation technology for use in high-value imaging and therapeutic applications which are commercialized through market-specific alliances with corporate partners. Lumiphore has exclusive licenses to the basic science developed at the University of California, Berkeley in the laboratory of Professor Kenneth N. Raymond, a world expert on lanthanide chemistry. For more information about Lumiphore, log onto www.lumiphore.com<
'/>"/>

SOURCE Lumiphore, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
3. Boston Scientific Announces FDA Clearance and CE Mark Approval for Advanix™ Biliary Stents
4. Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
5. Hanger Orthopedic Group, Inc. Announces Pricing of $200 Million of Senior Notes
6. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter and Nine-Months Ended September 30, 2010 and Declares Quarterly Dividend
7. K-V Pharmaceutical Company Announces Establishment of New Generic Marketing Subsidiary and Senior Executive Appointment
8. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
9. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
10. Amgen Announces Webcast of 2010 Third Quarter Financial Results
11. ERT to Announce Third Quarter 2010 Results on November 4, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... PARSIPPANY, N.J. , Aug. 3, 2015  LEO ... and Drug Administration (FDA) to include psoriasis as one ... Focused Drug Development Initiative i .  Psoriasis is an ... lives and subsequent comorbidities, affecting 7.5 million people in ... of LEO Pharma,s ongoing commitment to supporting patients living ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Researchers at Brigham and Women,s,Hospital found that patients taking ... effects were unrelated to relief from their pain,symptoms. ... examine the addictive,potential of this class of pain medicine, ... 25th Annual Meeting. , In ...
... Lethal ,Super, Strains of C.difficileCHICAGO, Jan. 28 ... scientists at The University of Nottingham are leading a ... one of the most lethal strains of hospital acquired ... technology developed in Nottingham to study the function of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 3
(Date:8/4/2015)... ... August 04, 2015 , ... Patients are ... offered by the world renowned Beverly Hills facelift surgeon , Dr. Paul ... surgery techniques helps individuals to achieve an outer appearance that meets their personal ...
(Date:8/4/2015)... & LAS VEGAS (PRWEB) , ... August 04, 2015 , ... ... the pitch schedule for vendor participating in The ISE® Lions’ Den and Jungle Lounge ... Spa at Aria in Las Vegas. , During the event, eight emerging security vendors, ...
(Date:8/4/2015)... Las Vegas, Nevada (PRWEB) , ... August 04, ... ... INTIMATELY FEMALE, a striking contemporary look at unique artistic expressions from a diverse ... Motel inside the Life Is Beautiful Music & Art Festival on September 25-27, ...
(Date:8/4/2015)... ... 04, 2015 , ... Data2Life , a Tel Aviv-based ... provide pharmaceutical and healthcare organizations with advanced intelligence on drug effects. The product ... filings (including the FDA and HealthCanada), social media and anonymized clinical electronic health ...
(Date:8/4/2015)... ... 2015 , ... METTLER TOLEDO has announced an upcoming online ... Lubrizol, Pfizer, and Merck. This free online seminar will be held on ... require informed decisions with limited process understanding. Established methods have been developed ...
Breaking Medicine News(10 mins):Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 2Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 3Health News:T.E.N. Releases Pitch Schedule for The ISE® Lions Den & Jungle Lounge 2015 4Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 2Health News:Data2Life Announces New System for Advance Intelligence on Drug Events 3Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2
... STANFORD, Calif. The immune system may play a critical ... therapies, according to a new study by researchers at the ... disable cancer-promoting genes called oncogenes are much more successful in ... by kind of immune cell called a T helper cell. ...
... improved planning of care and stronger relationships with physicians ... to a study by a Queen,s University professor. , ... every Canadian," says professor of Medicine and Epidemiology Daren ... Hospital. "But it,s not always happening. We know from ...
... (HealthDay News) -- Treatments designed to tackle childhood obesity ... education programs are as effective as those that enlist ... parent-only programs are also generally cheaper and more practical ... the parent-only group was not inferior in terms of ...
... Reporter , TUESDAY, Oct. 26 (HealthDay News) -- As ... prevented if people followed five simple healthy lifestyle recommendations, ... improve overall health as well -- include exercise, a ... healthy weight, the researchers say. "Even a modest ...
... to hormonal changes and inflammation has been awarded a ... study. The research programme at the National Institute ... led by Professor Julian Davis, a consultant endocrinologist at ... Manchester,s Developmental Biomedicine Research Group. He is working ...
... Wu has invented a portable scanner based on radio frequency technology, ... tumours malignant and benign in the breast on a ... detection has been proven by researchers in the US, Canada and ... for an image to be produced, and this had to be ...
Cached Medicine News:Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 2Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 3Health News:Certain cancer therapies' success depends on presence of immune cell, Stanford study shows in mice 4Health News:Parent-Only Programs Can Help Obese Kids Lose Weight: Study 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 2Health News: Healthy Living Can Prevent Nearly 25% of Colorectal Cancers 3Health News:Manchester team wins $1.9 million grant for 'cell control' study 2Health News:Portable breast scanner allows cancer detection in the blink of an eye 2
... Designed specifically to ... interventionalists, Sequitor facilitates the ... the peripheral vasculature for ... both uterine fibroid embolization ...
Reference Lab Interface (RLI)© for SRS Software, provides real-time processing of HL7 lab data directly into SRS Freedom Chart ManagerTM, producing an HTML form in the patients chart/tab, whil...
... technology innovation, the new Guidant VASOVIEW® 7 ... the VASOVIEW® platform. The new VASOVIEW® 7 ... familiar platform, combining ease of use with ... finesse into a proven system. Discover advanced ...
Patient Monitor...
Medicine Products: